The FDA has marked today’s international Rare Disease Day with a number of measures to promote research and patient participation in policy and research.
Bristol-Myers Squibb’s hopes of adding a new indication to the label for S1P modulator Zeposia have been dented after the drug failed a phase 3 trial in Crohn’s disease.